CheckMan Stock Market Overview

Tesla's months of promoting more affordable vehicles have reportedly not yielded more sales. As TechCrunch noted in a report Thursday (April 2), Elon Musk's electric vehicle (EV) company last year debuted scaled-back versions of its Model Y and Model 3 starting at $39,990 and $36,990 respectively.

Zoetis Inc. (ZTS) is rated a hold, as shares trade near fair value with limited upside despite sector leadership and defensive qualities. The company guides for 3-5% organic operational growth in 2026 and remains very shareholder-friendly, reflected in a 20% 5-year DPS growth and 6.6% buyback yield. Zoetis faces risks from pipeline concentration, potential margin pressure due to increasing competition and product setbacks, notably Librela's 32% sales decline due to safety concerns.

The iShares MSCI China A ETF (CNYA) offers exposure to over 400 onshore Chinese A-shares, emphasizing domestic economic drivers. CNYA has outperformed major Chinese ETFs on total and risk-adjusted returns, but suffers from high turnover, tracking error, and an unappealing income profile. Chinese GDP expectations for FY26 are the lowest in decades, while fiscal support this year is expected to be dialed down.

Arthur's acquisition spree drives more than 20% revenue growth, with 31 deals in 2025 and a strong pipeline fueling expansion into 2026.

JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.

Bayer advances AB-1002 after AskBio completes mid-stage study enrollment, as its Pharma strategy and pipeline milestones drive long-term growth outlook.

There's always opportunity in markets if you know where to look, says Tiffany McGhee. She offers insight into how her firm positions portfolios in times of profound volatility, including now as the U.S.-Iran War drags on.

LOS ANGELES, April 2, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Franklin BSP Realty Trust, Inc. ("FBRT" or the "Company") (NYSE: FBRT). IF YOU SUFFERED A LOSS ON YOUR FBRT INVESTMENTS, CLICK HERE BEFORE APRIL 27, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?

LOS ANGELES, April 2, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Grocery Outlet Holding Corp. ("Grocery Outlet" or the "Company") (NASDAQ: GO). IF YOU SUFFERED A LOSS ON YOUR GROCERY OUTLET INVESTMENTS, CLICK  HERE BEFORE MAY 15, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?

MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).